Clinical Trial Update: Phase II Study of AP0302 5% Versus a Vehicle Comparator [Phase 2]

View source ↗

Summary

Phase II study comparing AP0302 5% to vehicle for pain associated with delayed onset muscle soreness has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Delayed-onset Muscle Soreness
• Pain

Drugs mentioned

• AP0302 5%

Snippet

Sponsor: Aponia Laboratories, Inc. | Conditions: Pain, Delayed Onset Muscle Soreness | Phase 2 | Status: COMPLETED